Site-directed chemotherapy with a drug bound to anti-idiotypic antibody to a lymphoma cell-surface IgM.
Xenogeneic antibodies against the cell-surface IgM of a B-cell lymphoma (38C-13) were coupled through a dextran bridge to the anti-neoplastic drug, daunomycin. The conjugate maintained both its antibody and its drug activity. The effectiveness of the conjugate was tested in vivo in mice challenged with the 38C-13 lymphoma. Drug conjugates of the idiotypic antibodies injected intraperitoneally 2 days after tumor transplantation almost completely inhibited tumor development. The controls, daunomycin-dextran-goat anti-DNP, free daunomycin, or the antibodies alone had no effect or only delayed the tumor development.
D000818:Animals; D000918:Antibody Specificity; D003630:Daunorubicin / Q000008:administration & dosage*; D004353:Drug Evaluation, Preclinical; D007116:Immunization, Passive; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage; D007130:Immunoglobulin Idiotypes / Q000008:administration & dosage*; D007075:Immunoglobulin M / Q000276:immunology*; D008223:Lymphoma / Q000188:drug therapy* / Q000276:immunology; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000276:immunology; D011947:Receptors, Antigen, B-Cell / Q000276:immunology*
D007140:Immunoglobulin Fab Fragments; D007130:Immunoglobulin Idiotypes; D007075:Immunoglobulin M; D011947:Receptors, Antigen, B-Cell; D003630:Daunorubicin